X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1123) 1123
drug combinations (1113) 1113
male (934) 934
aged (901) 901
female (861) 861
middle aged (845) 845
oxonic acid - administration & dosage (816) 816
tegafur - administration & dosage (815) 815
antineoplastic combined chemotherapy protocols - therapeutic use (653) 653
oxonic acid - adverse effects (629) 629
tegafur - adverse effects (622) 622
oncology (591) 591
adult (584) 584
index medicus (582) 582
s-1 (532) 532
stomach neoplasms - drug therapy (475) 475
antineoplastic combined chemotherapy protocols - adverse effects (470) 470
chemotherapy (459) 459
oxonic acid - therapeutic use (417) 417
tegafur - therapeutic use (416) 416
treatment outcome (377) 377
cancer (365) 365
stomach neoplasms - pathology (300) 300
drug administration schedule (297) 297
5-fluorouracil (286) 286
cisplatin - administration & dosage (265) 265
aged, 80 and over (253) 253
antimetabolites, antineoplastic - adverse effects (241) 241
antimetabolites, antineoplastic - therapeutic use (227) 227
cisplatin (226) 226
neoplasm staging (218) 218
antimetabolites, antineoplastic - administration & dosage (214) 214
disease-free survival (212) 212
fluorouracil (211) 211
medicine & public health (206) 206
pharmacology & pharmacy (203) 203
administration, oral (201) 201
gastric cancer (189) 189
trial (188) 188
care and treatment (180) 180
survival rate (178) 178
antineoplastic combined chemotherapy protocols - administration & dosage (167) 167
cancer research (162) 162
stomach cancer (160) 160
research (159) 159
adenocarcinoma - drug therapy (151) 151
stomach neoplasms - surgery (145) 145
pyridines - administration & dosage (143) 143
carcinoma (142) 142
therapy (139) 139
retrospective studies (136) 136
clinical trials (134) 134
deoxycytidine - analogs & derivatives (130) 130
cisplatin - adverse effects (128) 128
chemotherapy, adjuvant (126) 126
pharmacology/toxicology (124) 124
oxaliplatin (123) 123
antineoplastic agents (121) 121
antimitotic agents (119) 119
stomach neoplasms - mortality (117) 117
camptothecin - analogs & derivatives (116) 116
capecitabine (116) 116
oncology, experimental (110) 110
metastasis (108) 108
gastrectomy (107) 107
docetaxel (104) 104
dose-response relationship, drug (104) 104
kaplan-meier estimate (103) 103
neoplasm metastasis (103) 103
surgery (103) 103
camptothecin - administration & dosage (101) 101
combined modality therapy (101) 101
survival (101) 101
lung neoplasms - drug therapy (100) 100
pyridines - adverse effects (96) 96
organoplatinum compounds - administration & dosage (94) 94
gemcitabine (93) 93
radiotherapy (93) 93
irinotecan (92) 92
survival analysis (92) 92
adjuvant chemotherapy (91) 91
cancer patients (89) 89
colorectal neoplasms - drug therapy (89) 89
pancreatic neoplasms - drug therapy (89) 89
adenocarcinoma (87) 87
lymphatic metastasis (87) 87
taxoids - administration & dosage (87) 87
fluorouracil - administration & dosage (85) 85
deoxycytidine - administration & dosage (84) 84
leucovorin (84) 84
time factors (84) 84
japan (82) 82
neoplasm recurrence, local - drug therapy (81) 81
phase-ii (81) 81
toxicity (81) 81
1st-line treatment (80) 80
adenocarcinoma - pathology (79) 79
combination (79) 79
maximum tolerated dose (79) 79
drug therapy (78) 78
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 141 - 148
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 3, pp. 215 - 221
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 18, pp. 1810 - 1820
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2011, Volume 68, Issue 1, pp. 157 - 164
Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety... 
Medicine & Public Health | Gemcitabine | Pancreatic cancer | Oncology | Cancer Research | Curcumin | Pharmacology/Toxicology | APOPTOSIS | ACTIVATION | CELL-PROLIFERATION | SUPPRESSION | I CLINICAL-TRIAL | 5-FLUOROURACIL | THERAPY | INHIBITION | ONCOLOGY | GENE-PRODUCTS | PHARMACOLOGY & PHARMACY | EXPRESSION | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Curcumin - administration & dosage | Pancreatic Neoplasms - drug therapy | Adenocarcinoma - physiopathology | Antineoplastic Agents - adverse effects | Deoxycytidine - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Pancreatic Neoplasms - mortality | Deoxycytidine - administration & dosage | Tegafur - adverse effects | Tegafur - therapeutic use | Curcumin - pharmacokinetics | Survival Rate | Curcumin - adverse effects | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Drug Synergism | Medication Adherence | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents - blood | Aged | Pancreatic Neoplasms - physiopathology | Deoxycytidine - analogs & derivatives | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Cancer patients | Chemotherapy | Gastrointestinal agents | Oncology, Experimental | Research | Cancer | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, pp. CD011746 - CD011746
Background Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocar-cinomas,... 
MEDICINE, GENERAL & INTERNAL | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | RANDOMIZED PHASE-II | DESIGN CHARACTERISTICS | FINDINGS TABLES | EMPIRICAL-EVIDENCE | GALLBLADDER CANCER | POOLED ANALYSIS | SINGLE-AGENT GEMCITABINE | TRIAL SEQUENTIAL-ANALYSIS | Capecitabine - administration & dosage | Gallbladder Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biliary Tract Neoplasms - mortality | Ampulla of Vater | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Oxaliplatin | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Mitomycin - adverse effects | Piperidines - administration & dosage | Tegafur - adverse effects | Cholangiocarcinoma - mortality | Oxonic Acid - administration & dosage | Oxonic Acid - adverse effects | Randomized Controlled Trials as Topic | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Capecitabine - adverse effects | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Gallbladder Neoplasms - pathology | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 90 - 98
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1125 - 1132
Journal Article